gilead sciences inc ˈɡɪliəd american biopharmaceutical company headquartered foster city california focuses researching developing antiviral drugs used treatment hivaids hepatitis b hepatitis c influenza including ledipasvirsofosbuvir sofosbuvir gilead member nasdaq biotechnology index sp gilead founded name oligogen michael l riordan original name reference oligomers small strands dna used target genetic sequences gilead held ipo successfully developed drugs like tamiflu vistide decade gilead received approval drugs including viread hepsera among others began evolving biotechnology company pharmaceutical company acquiring several subsidiaries though still relied heavily contracting manufacture drugs company continued growth however came heavy scrutiny business practices including extremely high pricing drugs sovaldi truvada united states relative production cost cost developing june gilead sciences originally founded name michael l riordan medical riordan graduated washington university st louis johns hopkins school medicine harvard business idea gilead began research project menlo ventures michael associate three scientific advisers worked riordan create company peter dervan caltech doug melton harvard harold weintraub fred hutchinson cancer research center along h dubose montgomery one menlo ventures founders riordan served ceo companys founding menlo ventures subsequently made first investment gilead riordan also recruited scientific advisers including harold varmus nobel laureate later became director national institutes health jack szostak recipient nobel prize physiology medicine companys primary therapeutic focus antiviral medicines field piqued riordans interest contracted dengue riordan recruited donald rumsfeld join board directors followed benno c schmidt srcitation needed gordon george p riordan tried recruit warren buffett investor board member company focused early research making small strands dna oligomers particularly oligonucleotides target specific genetic code sequences antisense therapy form gene according riordan always wanted use name gilead sciences along still used oligogen temporary name needed deal trademark clearance issue california nonprofit organization already using word gilead first heard balm gilead read lanford wilsons play balm gilead medical school learned naturally occurring acetylsalicylic acid aspirin found modern times willow tree species part world therefore inspired name company founding oligogen contacted nonprofit naming issue secured right use gilead sciences name exchange company moved headquarters foster citys vintage park neighborhood based ever company began develop small molecule antiviral therapeutics company inlicensed group nucleotide compounds including riordan later recalled gileads first decade startup extremely stressful experience young venture capitalist serving first time founder chairman chief executive officer biotech new company products little income narrowly escaped going business several occasions touch go long finding way gilead make money riordans top priority every second day eight gileads antisense intellectual property portfolio sold ionis pharmaceuticals gilead debuted nasdaq january initial public offering raised million proceedscitation needed june gilead launched vistide cidofovir injection treatment cytomegalovirus cmv retinitis patients january donald rumsfeld appointed chairman left board january appointed united states secretary defense george w bushs first term march gilead acquired nexstar pharmaceuticals boulder colorado time nexstars annual sales million three times gileads sales sold ambisome injectable fungal treatment daunoxome oncology drug taken hiv patients year roche announced fda approval tamiflu oseltamivir treatment tamiflu originally discovered gilead licensed roche latephase development one reason entering tamiflu licensing agreement employees gilead still yet capability sell drugs directly overseas avoid license future drugs order access international markets gilead simply acquired nexstar already built sales force europe market ambisome viread tenofovir achieved first approval treatment gilead changed corporate strategy focus exclusively antivirals sold cancer assets osi pharmaceuticals december gilead triangle pharmaceuticals announced gilead would acquire triangle around million triangles lead drug emtricitabine near fda approval two antivirals company also announced first full year profitability later year hepsera adefovir approved treatment chronic hepatitis b emtriva emtricitabine treatment hivcitation needed era gilead completed gradual evolution biotech startup pharmaceutical san francisco chronicle noted gilead corporate campus foster city expanded seven lowslung sandcolored buildings around tiny lake ducks happily like many startups gilead originally leased space company paid million buy headquarters buildings however even gilead developed ability distribute sell drugs remained distinct pharmaceutical companies terms strong reliance subcontracting manufacturing contract manufacturing avian flu pandemic scare gilead sciences revenue tamiflu almost quadrupled national governments stockpiled antiviral drug though firm made loss concern flu started stocks soared us defense secretary pentagon chief donald rumsfeld sold shares company receiving million capital gains still maintaining shares end year sales tamiflu almost quadrupled time share price tripled report showed rumsfeld owned shares worth got income gilead completed two acquisitions allowed company branch historical antiviral franchise cardiovascular respiratory therapeutic arenas company acquired corus pharma inc million acquisition corus signaled gileads entry respiratory arena corus developing aztreonam lysine treatment patients cystic fibrosis infected pseudomonas aeruginosacitation needed july us food drug administration fda approved atripla day single tablet regimen hiv combining sustiva efavirenz bristolmyers squibb product truvada emtricitabine tenofovir disoproxil gilead gilead purchased raylo chemicals inc november price raylo chemical based edmonton alberta wholly owned subsidiary degussa ag german company raylo chemical custom manufacturer active pharmaceutical ingredients advanced intermediates pharmaceutical biopharmaceutical industries later year gilead acquired myogen inc billion largest acquisition two drugs development ambrisentan darusentan one marketed product flolan pulmonary diseases acquisition myogen solidified gileads position therapeutic arena agreement glaxosmithkline myogen marketed flolan epoprostenol sodium united states treatment primary pulmonary hypertension additionally myogen developing phase studies also endothelin receptor antagonist potential treatment resistant hypertension gilead expanded move respiratory therapeutics entering licensing agreement parion epithelial sodium channel inhibitor treatment pulmonary diseases including cystic fibrosis chronic obstructive pulmonary disease company acquired cv therapeutics inc billion bringing ranexa lexiscan ranexa cardiovascular drug used treat chest pain related coronary artery disease products pipeline building gileads cardiovascular later year company named one fastest growing companies company acquired cgi pharmaceuticals million expanding gileads research expertise kinase biology chemistry later year company acquired arresto biosciences inc million obtaining developmentalstage research treating fibrotic diseases february company acquired calistoga pharmaceuticals million million plus milestone payments acquisition boosted gileads oncology inflammation later year gilead made important acquisition expensive billion purchase pharmasset inc transaction helped cement gilead leader treatment hepatitis c virus giving control sofosbuvir see october gilead broke ground massive multiyear expansion headquarters campus foster replacing eight one twostory buildings seven new structures ranging tall stories gilead nearly doubled headquarters real estate footprint square feet million square july fda approved gileads truvada prevention hiv infection already approved treating hiv pill preventive measure prep people high risk getting hiv sexual company acquired ym biosciences inc million acquisition brings drug candidate orallyadministered oncedaily selective inhibitor janus kinase jak family specifically gileads oncology pipeline jak enzymes implicated myeloproliferative diseases inflammatory disorders certain cancers company made trio acquisitions company acquired nimbus apollo inc million giving gilead control compound acc inhibitor preclinical acc inhibitors treatment nonalcoholic steatohepatitis potential treatment hepatocellular also company named generous company fortune list generous companies fortune charitable donations hivaids liver disease organizations totaled million august company announced would acquire kite pharma equating cash per share premium closing price shares deal gileads entry cell therapy market added chimeric antigen receptor cell cart therapy candidate companys acquisition led two marketed products lymphoma yescarta november company announced acquire cell design labs million indirectly acquired stake via kite pharma may us department health human services announced gilead sciences donate truvada drug approved prevent infection hiv free patients annually december hhs explained government would distribute donated drugs hhs secretary alex azar explained us government pay gilead per bottle pills costs associated getting drug factories eventual hands march company announced would acquire forty seven inc share billion april gilead completed acquisition forty seven inc per share net seller cash without interest approximately billion june bloomberg reported astrazeneca plc made preliminary approach gilead potential merger worth almost month company announced would acquire stake privately held pionyr immunotherapeutics inc september gilead announced reached deal acquire immunomedics billion per share gaining control cancer treatment trodelvy sacituzumab govitecanhziy firstinclass antibodydrug december business announced would acquire german biotech myr gmbh billion plus million myr focuses treatment chronic hepatitis delta august us senator rand paul disclosed wife kelley paul purchased stake gilead sciences february january gilead pulled cancer drug zydelig idelalisib accelerated approval relapsed follicular bcell nonhodgkin lymphoma fl relapsed small lymphocytic leukemia september company completed acquisition mirobio february business kite pharma completed acquisition tmunity may business announced would acquire xinthera small molecule drug sofosbuvir part acquisition pharmasset fda approved drug trade name sovaldi treatment hepatitis c virus forbes magazine ranked gilead number drug company citing market capitalization billion stock appreciation describing purchase pharmasset billion one best pharma acquisitions deutsche bank estimated sovaldi sales years final quarter would barrons noted fda approval subsequent strong sales potentially revolutionary drug positive indicator july united states senate committee finance investigated sovaldis high price per pill full regimen senators questioned extent market operating efficiently rationally committee chairman ron wyden doregon ranking minority member chuck grassley riowa wrote ceo john c martin asking gilead justify price committee hearings result new law due negotiated mandated discounts sovaldi sold well list poorer countries gilead licensed multiple companies produce generic versions sovaldi india pills price low gilead later combined sovaldi antivirals singlepill combinations first sovaldi combined ledipasvir marketed harvoni treatment hepatitis c cures patient cases hcv genotype gilead reporting drastic drops sovaldi revenue year year pricing pressure number suitable patients later singlepill combinations epclusa velpatasvir vosevi velpatasvir voxilaprevir fiscal year gilead sciences reported earnings billion annual revenue decline previous fiscal cycle gilead sciencess shares traded per share market capitalization valued billion october gileads challenge develop acquire new blockbuster drugs current revenueproducers wane patent protection expires gilead benefited expansion medicaid aca leerink analyst geoffrey porges wrote gileads hiv drugs could face funding pressure reform gilead billion cash billion outside us unavailable acquisitions unless gilead pays us tax though could borrow gilead would benefit proposals let companies repatriate offshore capital minimal gileads entospletinib shown complete response rate mll type acute myeloid leukaemia several mass tort lawsuits filed gilead alleging company deliberately delayed development antiretroviral drugs based tenofovir alafenamide fumarate taf order maximize profits previousgeneration medications containing tenofovir disoproxil fumarate plaintiffs allege gilead suspended taf despite clear evidence indicating tafbased medications safer tdf compound whose longterm use associated adverse side effects nephrotoxicity bone density gileads first taf medication marketed trade name genvoya came lawsuits allege interim period many hiv patients continuously took gileads older tdfbased drugs suffered severe side effects including gilead came intense criticism high pricing patented drug sofosbuvir sold brand name sovaldi used treat hepatitis us instance launched per pill standard drastically cheaper developing india dropped low per sovaldi represented significant improvement contemporary treatments controversy surrounding price ignited national debate us according united states senate committee finance launched investigation gileads sovaldi pricing argued report gilead set prices high disregard human cost order set stage higher eventual price sovaldis successor committees investigation based part internal documents obtained gilead revealed company considered prices ranging per year trying strike balance revenue predicted activist public relations blowback little regard research development high prices forced state medicaid programs ration treatment patients delaying treatment less advanced hepatitis c oregon example medicaid patients deemed good candidates sovaldi therapy oregon health authority estimated treating half patients would double states total drug expenditures state thus opted limit treatment patients per truvada introduced market gilead treat hiv following years united states government conducted research demonstrating truvada able prevent hiv infection us centers disease control holds patent use truvada preexposure prophylaxis gilead introduced truvada prep point prescription cost approximately per month united price increased despite generally costing less outside gilead made billion sales truvada high price drew ire activist groups act subject congressional hearing may gileads ceo defended pricing hearing noting large sums company spends hivaids activists pressured us government enforce patent truvada order combat high prices set may gilead announced would donate enough truvada treat patients annually years result discussions department health human services trump dr rochelle walensky noted donations still covered less onefifth people need drug argued possibly move help company market descovy advanced successor walensky led study concluded high costs descovy would whole negate comparative advantage prescribing generic truvada july gilead announced would decrease drug pricing program reimbursements clinics serving primarily lowincome communities clinics argued severely hinders ability provide hivaids prevention treatment services among vulnerable gilead also accused stifling competition lawsuit filed united states alleged company entered pay delay agreements manufacturers wherein manufacturers agreed delay releasing generic versions cvs pharmacy riteaid filed lawsuit similar grounds gilead bristolmyers squibb teva pharmaceuticals response criticisms price sovaldi gilead began licensing rights produce generic versions drug select producers india included licensing agreements antidiversion provisions designed prevent drug exported back developed countries cheaper generic alternatives still india onemonth treatment cost approximately versus per pill united gilead required indian producers screen patients determine could buy sovaldi criticized médecins sans frontières since could lead exclusion vulnerable groups like refugees migrants accessing response criticism gilead eventually relaxed gilead criticized tax avoidance tax avoidance opposed tax evasion use legal means shift tax burdens one jurisdiction overseas affiliates pay lower tax rate even revenue primarily generated outside overseas jurisdictioncitation needed report liberal think tank americans tax fairness argued gilead able avoid billion taxes us sales mechanisms transfer sale assets affiliated entities particular gilead sells intellectual property irish subsidiary sells finished products sovaldi united states elsewhere paying low irish tax rate practice common among multinational pharmaceutical companies like december times reported gilead used double irish arrangement avoid us corporate taxes global profits stating firm used controversial tax loophole arrangement shift almost billion profits irish entity two years without paying irish company repatriated portion irish subsidiarys holdings billion united states following reductions corporate tax rate paid estimated billion gilead sought obtained orphan drug designation remdesivir us food drug administration fda march designation intended encourage development drugs affecting fewer americans granting strengthened extended legal monopoly rights manufacturer along waivers taxes government remdesivir became candidate treating time status granted fewer americans numbers climbing rapidly pandemic reached us crossing threshold soon considered gilead retains remdesivir patents remdesivir tradename veklury generated billion annual revenues gileads highest selling emergency use authorization remdesivir granted us may people hospitalized severe september following review evidence issued guidance use remdesivir people good evidence however clinical research remdesivir approved treatment hospitalized people united states european union multiple canadian component international solidarity trial reported inhospital people treated remdesivir lower death rates reduced need oxygen mechanical ventilation compared people receiving standardofcare veklury received approval us food drug administration fda october use hospitalized adults children years older treatment severe january fda gave regulatory approval veklury use adults children years age older weigh least kilograms lb positive hospitalized ill high risk developing severe including hospitalization fda also provided emergency use authorization veklury treatment children age covidpositive hospitalized mildtomoderate high risk developing severe including hospitalization httpsenwikipediaorgwikigileadsciences